NOV 30, 2016 3:10 PM PST

South Africa Hosts Historic HIV Vaccine Trial

WRITTEN BY: Xuan Pham
South Africa will host the first large-scale study of a new HIV vaccine since 2009. Will the new vaccine be “the final nail in the coffin" for HIV? Scientists hope to find out within seven years time.

The trial, code named HVTN 702, is sponsored by the US National Institute of Health (NIH). Researchers anticipate enrolling a total of 5,400 healthy men and women over 18 years old, who will be given a new version of the only HIV vaccine candidate that showed modest effects against the retrovirus in a Thai study.
 
"[This study] will tell us whether the initial success observed [at a smaller scale] will bear fruit in the form of a safe and effective HIV vaccine designed for the people of southern Africa," said Glenda Gray said, head of South Africa's Medical Research Council.
 
In the Thai study, the HIV vaccine was 31.2 percent effective at preventing HIV infection. This rate of success was deemed modest, since it spanned over 3.5 years after vaccination. Nevertheless, researchers remain optimistic that any positive effects, even if modest, can improve the situation significantly. “Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID).
 
The current vaccine has 2 components: a canarypox vector-based vaccine called ALVAC-HIV, and a gp120 protein subunit vaccine to augment the body’s immune response. Because this treatment does not contain HIV itself, there is no risk of contracting HIV from the vaccines. Furthermore, the HVTN 702 vaccine has been modified to be specific to the HIV subtype C found in Southern Africa.
 

It is not by chance that the biggest HIV vaccine trial is being conducted in South Africa. This part of the world sees more than 1,000 new HIV infections everyday. “HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country. If an HIV vaccine were found to work in South Africa, it could dramatically alter the course of the pandemic,” said Gray.
 
Participants in the study will be randomized to receive either the vaccine or the placebo. Both groups will receive 5 injections over the course of 1 year, along with standard HIV prevention education. Should participants contract HIV, they will be referred to treatment facilities in accordance with standard practice. Though everyone is optimistic, the results will not be known for a few more years. Still, this trial is a landmark attempt at combatting HIV, and we are sure to learn much from this study. 

Additional sources: NIH, BBC
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 06, 2020
Clinical & Molecular DX
Your Earwax Says You're Depressed
NOV 06, 2020
Your Earwax Says You're Depressed
Cortisol, commonly known as the “stress hormone”, is the body’s built-in alarm system that sends siren ...
NOV 17, 2020
Clinical & Molecular DX
Tumor Stiffness Linked to Its Aggressiveness
NOV 17, 2020
Tumor Stiffness Linked to Its Aggressiveness
  As tumors grow, tiny areas at their cores are found to become stiff prior to metastasis, or the spread of cancer ...
DEC 02, 2020
Cancer
Investigating the Active Components of an Herbal Mushroom
DEC 02, 2020
Investigating the Active Components of an Herbal Mushroom
When people think of traditional medicine, often what comes to mind are the old herbal medical practices in Asian countr ...
DEC 01, 2020
Cardiology
The Benefits of Exercise on Adipokine Levels for Post-Menopausal Women
DEC 01, 2020
The Benefits of Exercise on Adipokine Levels for Post-Menopausal Women
The benefits of a healthy lifestyle don’t just stop when you get older. Being active has been shown to improve pos ...
DEC 24, 2020
Clinical & Molecular DX
Feeling Unmotivated? It Could Be Dementia.
DEC 24, 2020
Feeling Unmotivated? It Could Be Dementia.
Apathy, characterized by a pronounced lack of enthusiasm, motivation, or interest, is a predictor of the future onset of ...
FEB 25, 2021
Clinical & Molecular DX
A Better Way to Triage COVID Patients
FEB 25, 2021
A Better Way to Triage COVID Patients
Australian researchers have developed a COVID-19 triaging tool that serves as a crystal ball for healthcare workers. Onc ...
Loading Comments...